<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 11 (filtered medium)">
<style>
<!--
/* Font Definitions */
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman";}
a:link, span.MsoHyperlink
{color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{color:purple;
text-decoration:underline;}
p.regulartextchar, li.regulartextchar, div.regulartextchar
{mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:Arial;
color:black;}
span.emailstyle18
{font-family:Arial;
color:windowtext;}
span.announcetitle1
{font-family:Verdana;
font-weight:normal;}
span.style11
{font-family:Arial;}
span.regulartext1
{font-family:Arial;
color:black;
font-weight:normal;}
span.emailstyle22
{font-family:Arial;
color:navy;}
span.emailstyle24
{font-family:Arial;
color:navy;}
span.EmailStyle25
{mso-style-type:personal-reply;
font-family:"Times New Roman";
color:blue;
font-weight:normal;
font-style:normal;
text-decoration:none none;}
@page Section1
{size:8.5in 11.0in;
margin:1.0in 1.25in 1.0in 1.25in;}
div.Section1
{page:Section1;}
-->
</style>
<!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang=EN-US link=blue vlink=purple>
<div class=Section1>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
<div>
<p class=MsoNormal><b><font size=2 face=Tahoma><span style='font-size:10.0pt;
font-family:Tahoma;font-weight:bold'>From:</span></font></b><font size=2
face=Tahoma><span style='font-size:10.0pt;font-family:Tahoma'> Matthew Nelson
[mailto:MNelson@flinn.org] <br>
<b><span style='font-weight:bold'>Sent:</span></b> Monday, January 04, 2010
10:18 AM<br>
<b><span style='font-weight:bold'>Subject:</span></b> NIH Directors Opportunity
for Research in Five Thematic Areas (RC4)</span></font><o:p></o:p></p>
</div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'> <o:p></o:p></span></font></p>
<p class=MsoNormal style='line-height:16.8pt'><b><font size=1 color=black
face=Arial><span style='font-size:9.0pt;font-family:Arial;color:black;
letter-spacing:.15pt;font-weight:bold'>Scope.</span></font></b><font size=1
color=black face=Arial><span style='font-size:9.0pt;font-family:Arial;
color:black;letter-spacing:.15pt'> This grants program is aimed at research
endeavors that address one or more of the following five thematic areas:</span></font><o:p></o:p></p>
<p class=MsoNormal style='mso-margin-top-alt:0in;margin-right:0in;margin-bottom:
12.0pt;margin-left:.5in;text-indent:-.25in;line-height:16.8pt'><font size=1
color=black face=Arial><span style='font-size:9.0pt;font-family:Arial;
color:black;letter-spacing:.15pt'>1.</span></font><font size=1 color=black><span
style='font-size:7.0pt;color:black;letter-spacing:.15pt'>
</span></font><i><font size=1 color=black face=Arial><span style='font-size:
9.0pt;font-family:Arial;color:black;letter-spacing:.15pt;font-style:italic'>Applying
Genomics and Other High Throughput Technologies:</span></font></i><font size=1
color=black face=Arial><span style='font-size:9.0pt;font-family:Arial;
color:black;letter-spacing:.15pt'> In the past, many basic biomedical
science projects were limited in scope to some aspect of genetics, cell
biology, or physiology. The revolution now sweeping the field is the
ability to be comprehensive – for example, to define all of the genes of
the human, model organisms or the human microbiota, all of the human proteins
and their structures, or all of the major pathways for signal transduction in
the cell. Technologies contributing to these advances, many of which became
practical at scale only in the last few years, include DNA sequencing,
microarray technology, nanotechnology, small molecule screening capabilities,
new imaging modalities, and computational biology. These comprehensive
approaches coupled with systems-level integration, analysis and mining of large
datasets now hold the promise of major advances in the understanding of the
mechanisms of diseases. </span></font><o:p></o:p></p>
<p class=MsoNormal style='mso-margin-top-alt:0in;margin-right:0in;margin-bottom:
12.0pt;margin-left:.5in;text-indent:-.25in;line-height:16.8pt'><font size=1
color=black face=Arial><span style='font-size:9.0pt;font-family:Arial;
color:black;letter-spacing:.15pt'>2.</span></font><font size=1 color=black><span
style='font-size:7.0pt;color:black;letter-spacing:.15pt'>
</span></font><i><font size=1 color=black face=Arial><span style='font-size:
9.0pt;font-family:Arial;color:black;letter-spacing:.15pt;font-style:italic'>Translating
Basic Science Discoveries into New and Better Treatments:</span></font></i><font
size=1 color=black face=Arial><span style='font-size:9.0pt;font-family:Arial;
color:black;letter-spacing:.15pt'> Armed with a wealth of basic science
discoveries and an understanding of the pathophysiology of various diseases, we
are embarking on the next frontier in designing new diagnostic and therapeutic
strategies. Molecular and cellular insights into a disease can be
developed into screening assays on hundreds of thousands of compounds, and
tested in disease models to identify the most promising leads that can sustain
the drug development pipeline and attract public-private partnerships for
further pursuits. Additional pathways to therapeutics from gene therapy,
biologics, and stem cells (including iPS cells) are also showing great promise.
The opportunity is here for translational science to develop small
molecule-based, gene-based, protein/peptide-based and cell-based therapies for
common as well as rare diseases. </span></font><o:p></o:p></p>
<p class=MsoNormal style='mso-margin-top-alt:0in;margin-right:0in;margin-bottom:
12.0pt;margin-left:.5in;text-indent:-.25in;line-height:16.8pt'><font size=1
color=black face=Arial><span style='font-size:9.0pt;font-family:Arial;
color:black;letter-spacing:.15pt'>3.</span></font><font size=1 color=black><span
style='font-size:7.0pt;color:black;letter-spacing:.15pt'>
</span></font><i><font size=1 color=black face=Arial><span style='font-size:
9.0pt;font-family:Arial;color:black;letter-spacing:.15pt;font-style:italic'>Using
Science to Enable Health Care Reform</span></font></i><font size=1 color=black
face=Arial><span style='font-size:9.0pt;font-family:Arial;color:black;
letter-spacing:.15pt'>: Quality, affordable health care for all Americans
cannot occur without significant advances in the underlying science that will
enable effective and efficient disease prevention and diagnosis, as well as
better and cheaper treatments to be identified. Clinical research
targeted toward health disparities, social and behavioral factors, large-scale
prospective population cohort analysis, comparative effectiveness,
cost-effective prevention and personalized medicine, and pharmacogenomics will
allow us to assess and mitigate disease risks, predict outcome and optimize
treatment. Health services research that includes health information
technology and health research economics will enhance the safety, quality and
efficiency of the health care delivery system, as well as facilitate health
promotion.</span></font><o:p></o:p></p>
<p class=MsoNormal style='mso-margin-top-alt:0in;margin-right:0in;margin-bottom:
12.0pt;margin-left:.5in;text-indent:-.25in;line-height:16.8pt'><font size=1
color=black face=Arial><span style='font-size:9.0pt;font-family:Arial;
color:black;letter-spacing:.15pt'>4.</span></font><font size=1 color=black><span
style='font-size:7.0pt;color:black;letter-spacing:.15pt'>
</span></font><i><font size=1 color=black face=Arial><span style='font-size:
9.0pt;font-family:Arial;color:black;letter-spacing:.15pt;font-style:italic'>Focusing
on Global Health:</span></font></i><font size=1 color=black face=Arial><span
style='font-size:9.0pt;font-family:Arial;color:black;letter-spacing:.15pt'>
The NIH has a long tradition of supporting the discovery phase of solutions to
major global health challenges, and recent scientific advances in genomics,
small molecule screening technologies, and vaccine development portend the
possibility of further major impacts on some of the most challenging and
harmful diseases worldwide. This theme encourages a greater focus on
global health and new emphasis on formulating prevention and intervention
strategies to tackle a number of infectious and parasitic diseases, chronic
non-communicable diseases and injuries, and other neglected diseases striking
the developing world, with the goal to reduce morbidity and mortality
associated with these diseases worldwide.</span></font><o:p></o:p></p>
<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in;line-height:16.8pt'><font
size=1 color=black face=Arial><span style='font-size:9.0pt;font-family:Arial;
color:black;letter-spacing:.15pt'>5.</span></font><font size=1 color=black><span
style='font-size:7.0pt;color:black;letter-spacing:.15pt'>
</span></font><i><font size=1 color=black face=Arial><span style='font-size:
9.0pt;font-family:Arial;color:black;letter-spacing:.15pt;font-style:italic'>Reinvigorating
the Biomedical Research Community:</span></font></i><font size=1 color=black
face=Arial><span style='font-size:9.0pt;font-family:Arial;color:black;
letter-spacing:.15pt'> The lifeblood of biomedical research in the United
States rests upon the talent and dedication of its scientists and the support
of innovative research. This theme encourages investigators to cultivate
new collaborations and to assemble multidisciplinary or interdisciplinary teams
in conducting innovative research on the most challenging biomedical and
behavioral areas. The goal is to strengthen our research capacity,
to broaden our research base and to enhance cross-fertilization of disciplines
by recruiting new investigators and new expertise into the research community,
and by developing and retaining these talents in a collaborative environment
that fosters creativity and exploration. </span></font><o:p></o:p></p>
<p class=MsoNormal><span class=announcetitle1><font size=3 face=Verdana><span
style='font-size:12.0pt'> </span></font></span><o:p></o:p></p>
<p class=MsoNormal><span class=announcetitle1><font size=1 face=Verdana><span
style='font-size:9.0pt'> </span></font></span><o:p></o:p></p>
<p class=MsoNormal><span class=announcetitle1><font size=1 face=Verdana><span
style='font-size:9.0pt'>Recovery Act Limited Competition: NIH Directors
Opportunity for Research in Five Thematic Areas (RC4)</span></font></span><br>
<span class=style11><font size=1 face=Arial><span style='font-size:9.0pt'>(RFA-OD-10-005)</span></font></span><font
size=1 face=Arial><span style='font-size:9.0pt;font-family:Arial'><br>
<span class=style11><font face=Arial>National Institutes of Health</font></span><br>
<span class=style11><font face=Arial>John E. Fogarty International Center</font></span><br>
<span class=style11><font face=Arial>National Center for Complementary and
Alternative Medicine</font></span><br>
<span class=style11><font face=Arial>National Cancer Institute</font></span><br>
<span class=style11><font face=Arial>National Center for Minority Health and
Health Disparities</font></span><br>
<span class=style11><font face=Arial>National Center for Research Resources</font></span><br>
<span class=style11><font face=Arial>National Eye Institute</font></span><br>
<span class=style11><font face=Arial>National Human Genome Research Institute</font></span><br>
<span class=style11><font face=Arial>National Heart, Lung, and Blood Institute</font></span><br>
<span class=style11><font face=Arial>National Institute on Aging</font></span><br>
<span class=style11><font face=Arial>National Institute on Alcohol Abuse and
Alcoholism</font></span><br>
<span class=style11><font face=Arial>National Institute of Allergy and
Infectious Diseases</font></span><br>
<span class=style11><font face=Arial>National Institute of Arthritis and
Musculoskeletal and Skin Diseases</font></span><br>
<span class=style11><font face=Arial>National Institute of Biomedical Imaging
and Bioengineering</font></span><br>
<em><i><font face=Arial><span style='font-family:Arial'>Eunice Kennedy Shriver</span></font></i></em><span
class=style11><font face=Arial> National Institute of Child Health and Human
Development </font></span><br>
<span class=style11><font face=Arial>National Institute on Drug Abuse</font></span><br>
<span class=style11><font face=Arial>National Institute on Deafness and Other
Communication Disorders</font></span><br>
<span class=style11><font face=Arial>National Institute of Dental and
Craniofacial Research</font></span><br>
<span class=style11><font face=Arial>National Institute of Diabetes and
Digestive and Kidney Diseases</font></span><br>
<span class=style11><font face=Arial>National Institute of Environmental Health
Sciences</font></span><br>
<span class=style11><font face=Arial>National Institute of General Medical
Sciences</font></span><br>
<span class=style11><font face=Arial>National Institute of Mental Health</font></span><br>
<span class=style11><font face=Arial>National Institute of Neurological
Disorders and Stroke</font></span><br>
<span class=style11><font face=Arial>National Institute of Nursing Research</font></span><br>
<span class=style11><font face=Arial>National Library of Medicine</font></span><br>
<span class=style11><font face=Arial>American Reinvestment and Recovery Act of
2009</font></span><br>
<span class=style11><font face=Arial>Application Receipt Date(s): March 15,
2010 </font></span><br>
<span class=style11><font face=Arial><a
href="http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-10-005.html"
title="blocked::http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-10-005.html">http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-10-005.html</a></font></span></span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'> </span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Matthew Nelson, MBA</span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Assistant Vice President</span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Research Programs</span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>The Flinn Foundation</span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>1802 N. Central Ave</span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Phoenix AZ 85004-1506</span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Office: (602) 744 6839</span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Mobile: (602) 459 6613</span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Fax: (602) 744 6815</span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'>Email: <a href="mailto:mnelson@flinn.org"
title="mailto:mnelson@flinn.org">mnelson@flinn.org</a></span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'><a href="http://www.flinn.org/bio-briefs/topic/research"
title="http://www.flinn.org/bio-briefs/topic/research">http://www.flinn.org/bio-briefs/topic/research</a></span></font><o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'><a href="http://www.flinn.org/bio-briefs/topic/Research"></a></span></font> <o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'><a href="http://azbioscientist.blogspot.com"></a></span></font> <o:p></o:p></p>
<p class=MsoNormal><font size=2 face=Arial><span style='font-size:10.0pt;
font-family:Arial'><a href="http://www.azbioscientist2.blogspot.com"></a></span></font> <o:p></o:p></p>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'> <o:p></o:p></span></font></p>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'> <o:p></o:p></span></font></p>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'> <o:p></o:p></span></font></p>
<p class=MsoNormal><i><font size=1 color=black face=Verdana><span
style='font-size:9.0pt;font-family:Verdana;color:black;font-style:italic'>This
e-mail and any attachments may contain privileged information and are therefore
considered confidential. Any disclosure, copying, distribution, or forwarding
of this e-mail or any attachments without permission of the sender is
prohibited. If you have received this e-mail in error, please delete it from
your system and notify the sender immediately. Thank you.</span></font></i><o:p></o:p></p>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'> <o:p></o:p></span></font></p>
</div>
</body>
</html>